ppraisal[J].IntJCardiol,2015,180:246-254[8]JanuaryCT,WannLS,AlpertJS,etal.2014AHA/ACC/HRSGuidelinefortheManagementofPatientsWithAtrialFibrillation:ExecutiveSummary[J].JournaloftheAmericanCollegeofCardiology,2014,64(21):2246-2280.[9]LarsenTB,SkjøthF,parativeeffectivenessandsafetyofnon-vitaminKantagonistoralanticoagulantsandwarfarininpatientswithatrialfibrillation:propensityweightednationwidecohortstudy[J].BritishMedicalJournal,2016:1-9.[10]LauffenburgerJC,FarleyJF,GehiAK,etal.EffectivenessandSafetyofDabigatranandWarfarininReal‐WorldUSPatientsWithNon‐ValvularAtrialFibrillation:ARetrospectiveCohortStudy[J].JournaloftheAmericanHeartsociation,2015,4(4):e001798-e001798.[11]ConnollySJ,EzekowitzMD,YusufS,etal.Dabigatranversuswarfarininpatientswithatrialfibrillation[J].NEnglJMed,2009,361:1139-1151.
全文预览
